pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Summary

Six patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion, two lesions, or three lesions, as a monotherapy (a maximum of three lesions could be injected). These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-7 business days for any delayed adverse events.

Timeline

Start

2018-11-05

Primary completion

2020-07-10

Completion

2020-11-30

Drugs

Indications